
NYSEHealthcareDrug Manufacturers - General
最新数据
US$174.35
−US$1.06 · -0.60%
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
前收盘价
US$174.35
−US$1.06 · -0.60%
盘中时间采用ET。市场数据可能有所延迟。
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
日内区间
当前US$174.35
52周区间
当前US$174.35
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
91
深度低估
情绪
52
多空交织
风险
31
中等风险
动量
44
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
日内区间
当前US$174.35
52周区间
当前US$174.35
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 587.39亿 USD | 540.73亿 USD | 458.11亿 USD | 443.51亿 USD | 374.17亿 USD |
| 销货成本 | 106.33亿 USD | 102.07亿 USD | 82.68亿 USD | 123.91亿 USD | 124.37亿 USD |
| 毛利 | 481.06亿 USD | 438.66亿 USD | 375.43亿 USD | 319.6亿 USD | 249.8亿 USD |
| 研究与开发 | 142.32亿 USD | 135.83亿 USD | 109.35亿 USD | 97.62亿 USD | 97.36亿 USD |
| 销售、一般及管理费用 | 205.12亿 USD | 202.24亿 USD | 182.22亿 USD | 179.84亿 USD | 155.9亿 USD |
| 营业费用 | 343.63亿 USD | 338.63亿 USD | 293.5亿 USD | 282.03亿 USD | 239.24亿 USD |
| 利息收入 | 3.6亿 USD | 3.45亿 USD | 3.01亿 USD | 8100万 USD | 4300万 USD |
| 利息支出 | 16.94亿 USD | 16.82亿 USD | 15.89亿 USD | 13.3亿 USD | 12.76亿 USD |
| 折旧和摊销 | 57.33亿 USD | 50.65亿 USD | 49.34亿 USD | 52.54亿 USD | 41.02亿 USD |
| 营业利润 | 137.43亿 USD | 100.03亿 USD | 81.93亿 USD | 37.57亿 USD | 10.56亿 USD |
| 净利润 | 102.55亿 USD | 70.35亿 USD | 59.55亿 USD | 32.88亿 USD | 1.12亿 USD |
公司数据更新于 2026年11月22日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Dimensional International High Profitability ETFDIHP6257.68万0.99%62.14亿 USD0.27%US$31.59-2.35%
WisdomTree International Hedged Quality Dividend Growth FundIHDG5877.22万2.88%21.11亿 USD0.58%US$49.47-2.66%
Dimensional - International Core Equity 2 ETFDFIC5106.04万0.35%144.85亿 USD0.22%US$34.86-2.41%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ3939.36万3.08%12亿 USD0.48%US$32.48-3.39%
VanEck Pharmaceutical ETFPPH3779.52万3.70%10.21亿 USD0.36%US$114.85-0.09%
First Trust Value Line Dividend Index FundFVD3353.87万0.42%79.19亿 USD0.62%US$49.92-0.46%
Dimensional World ex U.S. Core Equity 2 ETFDFAX2450.27万0.21%112.84亿 USD0.28%US$32.48-3.53%
WisdomTree International Quality Dividend Growth FundIQDG1970.79万2.92%6.87亿 USD0.42%US$39.62-2.46%
Dimensional International High Profitability ETFDIHP
WisdomTree International Hedged Quality Dividend Growth FundIHDG
Dimensional - International Core Equity 2 ETFDFIC
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ
VanEck Pharmaceutical ETFPPH
First Trust Value Line Dividend Index FundFVD
Dimensional World ex U.S. Core Equity 2 ETFDFAX
WisdomTree International Quality Dividend Growth FundIQDGAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。